PEN Quote, Financials, Valuation and Earnings

Globus Medical, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 15.47%. Penumbra, Inc.'s return on equity of 13.4% beat Globus Medical, Inc.'s return on equity of 10.08%.

Penumbra, Inc. has a consensus price target of $348.53, signalling upside risk potential of 2.2%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 22.04%. Given that Globus Medical, Inc. has higher upside potential than Penumbra, Inc., analysts believe Globus Medical, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.816, which suggesting that the stock is 18.405% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Globus Medical, Inc. quarterly revenues of $769M. Penumbra, Inc.'s net income of $45.9M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 81.50x while Globus Medical, Inc.'s PE ratio is 28.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 10.02x versus 4.37x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Holdings, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of -2.7%. Penumbra, Inc.'s return on equity of 13.4% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.

Penumbra, Inc. has a consensus price target of $348.53, signalling upside risk potential of 2.2%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $221.27 which suggests that it could grow by 51.07%. Given that iRhythm Holdings, Inc. has higher upside potential than Penumbra, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.816, which suggesting that the stock is 18.405% less volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.245%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

Penumbra, Inc. quarterly revenues are $354.7M, which are larger than iRhythm Holdings, Inc. quarterly revenues of $192.9M. Penumbra, Inc.'s net income of $45.9M is higher than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 81.50x while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 10.02x versus 6.62x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rapt Therapeutics, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of --. Penumbra, Inc.'s return on equity of 13.4% beat Rapt Therapeutics, Inc.'s return on equity of -67.79%.

Penumbra, Inc. has a consensus price target of $348.53, signalling upside risk potential of 2.2%. On the other hand Rapt Therapeutics, Inc. has an analysts' consensus of $58.00 which suggests that it could fall by -0.04%. Given that Penumbra, Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Penumbra, Inc. is more attractive than Rapt Therapeutics, Inc..

Penumbra, Inc. has a beta of 0.816, which suggesting that the stock is 18.405% less volatile than S&P 500. In comparison Rapt Therapeutics, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.241%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapt Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Rapt Therapeutics, Inc. pays out -- of its earnings as a dividend.

Penumbra, Inc. quarterly revenues are $354.7M, which are larger than Rapt Therapeutics, Inc. quarterly revenues of --. Penumbra, Inc.'s net income of $45.9M is higher than Rapt Therapeutics, Inc.'s net income of -$17.6M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 81.50x while Rapt Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 10.02x versus 54.16x for Rapt Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 12.93% compared to Penumbra, Inc.'s net margin of 11.55%. Penumbra, Inc.'s return on equity of 13.4% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

Penumbra, Inc. has a consensus price target of $348.53, signalling upside risk potential of 2.2%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.74 which suggests that it could grow by 14.27%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Penumbra, Inc., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Penumbra, Inc..

Penumbra, Inc. has a beta of 0.816, which suggesting that the stock is 18.405% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.12%.

Penumbra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 1.07% to investors and pays a quarterly dividend of $0.24 per share. Penumbra, Inc. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra, Inc. quarterly revenues are $354.7M, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. Penumbra, Inc.'s net income of $45.9M is lower than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, Penumbra, Inc.'s price-to-earnings ratio is 81.50x while Zimmer Biomet Holdings, Inc.'s PE ratio is 22.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra, Inc. is 10.02x versus 2.24x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.